Skip to main content
. Author manuscript; available in PMC: 2022 Sep 30.
Published in final edited form as: Stroke. 2020 Jun 17;51(7):2058–2065. doi: 10.1161/STROKEAHA.119.028713

Figure 1.

Figure 1.

Major Ischemic Events, Ischemic Stroke, Stroke, Major Hemorrhage, and Minor Hemorrhage in POINT by treatment group and by CYP2C19 metabolizer phenotype (as defined by the CHANCE trial)

Abbreviations: POINT, Platelet-oriented Inhibition in New TIA and minor ischemic stroke trial; CHANCE, Clopidogrel in High-risk patients with Acute Non-disabling Cerebrovascular Events trial; CI, confidence interval; NE, not estimable